TRPM8 antagonist 2
CAS No. 259674-19-6
TRPM8 antagonist 2 ( —— )
Catalog No. M20423 CAS No. 259674-19-6
TRPM8 antagonist 2 is a potent and selective TRPM8 antagonist with an IC50 of 0.2 nM used in the research of neuropathic pain syndromes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 69 | In Stock |
|
10MG | 113 | In Stock |
|
25MG | 195 | In Stock |
|
50MG | 309 | In Stock |
|
100MG | 514 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTRPM8 antagonist 2
-
NoteResearch use only not for human use.
-
Brief DescriptionTRPM8 antagonist 2 is a potent and selective TRPM8 antagonist with an IC50 of 0.2 nM used in the research of neuropathic pain syndromes.
-
DescriptionTRPM8 antagonist 2 is a potent and selective TRPM8 antagonist with an IC50 of 0.2 nM used in the research of neuropathic pain syndromes.
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetTRP/TRPV Channel
-
RecptorTRPM8
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number259674-19-6
-
Formula Weight398.5
-
Molecular FormulaC26H26N2O2?
-
Purity>98% (HPLC)
-
SolubilityDMSO:160 mg/mL (401.51 mM)
-
SMILESCOC(=O)[C@H](Cc1c[nH]c2ccccc12)N(Cc1ccccc1)Cc1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Alessia B Nunzio I Carmine O et al. Identification of a Potent Tryptophan-based TRPM8 Antagonist With in vivo Analgesic Activity[J]. Journal of Medicinal Chemistry 2018:acs.jmedchem.8b00545-.
molnova catalog
related products
-
TRPV4 agonist-1 free...
TRPV4 agonist-1 free base?is an agonist of transient receptor potential vanilloid 4 (TRPV4;EC50 of 60 nM, in the hTRPV4 Ca2+ assay).
-
AMG-9810
A potent, selective and competitive TRPV1 antagonist with IC50 of 24.5 and 85.6 nM for human and rat TRPV1, repectively.
-
Berbamine
Berbamine and its derivatives are promising agents to suppress liver cancer growth by targeting CAMKII.